Document is current
Any future updates will be listed below
-
Authors
Zhang, Xiaolu
Garnerone, Silvano
Simonetti, Michele
Harbers, Luuk https://orcid.org/0000-0003-3910-6497
Nicoś, Marcin https://orcid.org/0000-0002-9566-113X
Mirzazadeh, Reza
Venesio, Tiziana
Sapino, Anna https://orcid.org/0000-0003-3542-9571
Hartman, Johan https://orcid.org/0000-0002-6500-8527
Marchiò, Caterina
Bienko, Magda https://orcid.org/0000-0002-6499-9082
Crosetto, Nicola https://orcid.org/0000-0002-3019-6978
-
Funding
Funding for this research was provided by:
--Swedish Foundation for Medical Research
Vetenskapsrådet (621-2014-5503)
--Ragnar Soderberg Foundation
Cancerfonden
Stiftelsen för Strategisk Forskning
--Strategic Programme in Cancer at Karolinska Institute (StratCan) --Ragnar Soderberg Foundation
- License Information
-
More Information
Article History
Received: 4 November 2018
Accepted: 17 September 2019
First Online: 18 October 2019
Competing interests
: J.H. is a scientific advisor of Visiopharm AG and has been in advisory boards for AstraZeneca and Novartis. He has obtained speaker honoraria from Roche/FoundationMedicine. All the other authors declare no competing interests.
